Belli L, Ambrona M S, Gennaro E A, Isola E H, González Rescigno G R
J Int Med Res. 1983;11(1):32-7. doi: 10.1177/030006058301100107.
A total of 103 patients with acute gonococcal urethritis were treated with a single 1,200 mg dose of rifampicin. A 91 . 3% cure rate was obtained, as proved by the negative bacteriological controls effected on the 7th and 14th days after the initiation of therapy. Three pharyngeal infections and one ano-rectal infection responded successfully to the treatment. No signs of drug intolerance were detected with the stated dose. Reactivity to the VDRL test was not impaired during the duration of the study and three reactive cases were discovered. In previous studies of gonorrhoea we had observed a significant discrepancy between urine cultures and the urethral smears and, in view of this, it was decided to adopt the latter alone as a routine procedure. The proposed dose does not originate resistance to rifampicin in either the Hansen or Koch bacilli.
103例急性淋菌性尿道炎患者接受了单次1200毫克利福平治疗。治疗开始后第7天和第14天进行的细菌学阴性对照证明，治愈率为91.3%。3例咽部感染和1例肛门直肠感染对治疗反应良好。在规定剂量下未检测到药物不耐受迹象。在研究期间，VDRL试验的反应性未受损害，发现了3例反应性病例。在之前的淋病研究中，我们观察到尿液培养和尿道涂片之间存在显著差异，鉴于此，决定仅采用尿道涂片作为常规程序。建议的剂量不会使汉森氏杆菌或结核杆菌对利福平产生耐药性。
